A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Phase 2 Not yet recruiting 36 enrolled Afasci Inc

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the safety and exploratory efficacy of AFA-281 in patients with Alcohol use disorder on cravings, subjective response to alcohol, pain thresholds, anxiety, depression, and sleep.

Timeline

Start: 2025-10-01
Primary completion: 2027-06-01
Completion: 2027-12-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	AFA-281	Small molecule	60 mg	Oral
Comparator	AFA-281	Small molecule	120 mg	Oral

A Study of the Safety and Exploratory Efficacy of Oral AFA-281 in Patients with Alcohol Use Disorder

Summary

Timeline

Drugs

Indications